Beneficial effect of ET(A) receptor blockade in a rat model of radiocontrast-induced nephropathy

Renal Failure

Volumn 19, Issue 6, 1997, Pages 753-761

  Pollock, David M ^a,b   Polakowski, James S ^a   Wegner, Craig D ^a   Opgenorth, Terry J ^a  

^a ABBOTT LABORATORIES   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; ATRASENTAN; CARBON 14; CONTRAST MEDIUM; CREATININE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; INDOMETACIN; INULIN; MEGLUMINE DIATRIZOATE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROSTANOID; TRITIUM; WATER; DIATRIZOATE; ENDOTHELIN; ENDOTHELIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HEMATOCRIT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; RAT; ACUTE KIDNEY FAILURE; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; STEREOISOMERISM; URINE;

ANIMALS; CONTRAST MEDIA; CREATININE; DIATRIZOATE; DISEASE MODELS, ANIMAL; ENDOTHELINS; INDOMETHACIN; KIDNEY FAILURE, ACUTE; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PROSTAGLANDIN ANTAGONISTS; PROTEINURIA; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; STEREOISOMERISM;

EID: 0031283307     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.3109/08860229709037215     Document Type: Article

References (11)

1. Heyman SN, Clark BA, Cantley L, Spokes K, Rosen S, Brezis M, Epstein FH: Effects of ioversol versus iothalamate on endothelin release and radiocontrast nephropathy. Invest Radiol 28:313-318, 1993.
2. Heyman SN, Clark BA, Kaiser N, Spokes K, Rosen S, Brezis M, Epstein FH: Radiocontrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol 3:58-65, 1992.
3. Margulies KB, Hildebrand FL, Heublein DM, Burnett JC Jr: Radiocontrast increases plasma and urinary endothelin. J Am Soc Nephrol 2:1041-1045, 1991.
4. Cantley LG, Spokes K, Clark B, McMahon EG, Carter J, Epstein FH: Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int 44:1217-1223, 1993.
5. Rich MW, Crecelius CA: Incidence, risk factors and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. Arch Intern Med 150:1237-1242, 1990.
6. Weisberg LS, Kurnik PB, Kurnik BRC: Radiocontrast-induced nephropathy in humans: role of renal vasoconstriction. Kidney Int 41:1408-1415, 1992.
7. Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M: Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicify in the rat. J Clin Invest 94:1069-1975, 1994.
8. Bird E, Giancarli M, Megill JR, Durham S: Effects of endothelin in radiocontrast-induced nephropathy in rats are mediated through endothelin-A receptors. J Am Soc Nephrol 7:1153-1157, 1995.
9. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB, Gehrke LJ, Hernandez L, Magnuson SR, Marsh KC, Novosad EI, von Geldern TW, Wessale JL, Winn M, Wu-Wong JR: Pharmacological characterization of A-127722: An orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 276:473-481, 1996.
10. A selective endothelin receptor antagonists. 1. Discovery of A-127722. J Med Chem 39:1039-1048, 1996.
11. Oldroyd S, Haylor JL, Morcos SK: Bosentan, an orally active endothelin antagonist: effect on the renal response to contrast media. Radiology 196:661-665, 1995.